Get Instant Newsletter Alerts to your Mobile Device and Email as soon as the News or Alerts hit the wire.
PhaseBio Pharmaceuticals Inc. (OTC : PHASQ) Stock
MWN-AI** Summary
MWN-AI** Analysis
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Description
PhaseBio Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies to treat orphan diseases, with an initial focus on cardiopulmonary indications. The lead product candidate of the company is PB2452, which is a novel reversal agent for the antiplatelet drug ticagrelor, used for the treatment of patients experiencing major bleeding or those who require urgent surgery. It is also developing PB1046 which is a fusion protein for the treatment of pulmonary arterial hypertension. The company is also developing its preclinical product candidate, PB6440, for treatment-resistant hypertension.
Quote
| Last: | $1e-06 |
|---|---|
| Change Percent: | 100.0% |
| Open: | $0 |
| Close: | $1e-06 |
| High: | $0 |
| Low: | $0 |
| Volume: | 14 |
| Last Trade Date Time: | 12/31/1969 07:00:00 pm |
Stock Data
| Market Cap: | $50 |
|---|---|
| Float: | 45,326,013 |
| Insiders Ownership: | 0.19% |
| Institutions: | 7 |
| Short Percent: | 2066603% |
| Industry: | Biotechnology & Life Sciences |
| Sector: | Healthcare |
| Country: | US |
| City: |
Recent News Releases
Subscribe to Our Newsletter
**MWN-AI FAQ is based on asking OpenAI questions about PhaseBio Pharmaceuticals Inc. (OTC: PHASQ).
